Last reviewed · How we verify
Anti Fungal Drug
Anti Fungal Drug is a Small molecule drug developed by University of California, San Francisco. It is currently in Phase 3 development for Fungal infections (specific indication not specified).
This antifungal drug inhibits fungal cell wall or membrane synthesis to prevent fungal growth and proliferation.
This antifungal drug inhibits fungal cell wall or membrane synthesis to prevent fungal growth and proliferation. Used for Fungal infections (specific indication not specified).
At a glance
| Generic name | Anti Fungal Drug |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
While the specific molecular target is not provided, antifungal drugs typically work by disrupting critical fungal cell structures such as the cell wall (e.g., β-glucan synthesis inhibitors) or cell membrane (e.g., ergosterol synthesis inhibitors). This causes fungal cell death or growth inhibition. The exact mechanism for this UCSF investigational compound would depend on its specific molecular target.
Approved indications
- Fungal infections (specific indication not specified)
Common side effects
Key clinical trials
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
- Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (PHASE1, PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
- Alternation in the Human Microbiome With Commonly Used Topical Medications (PHASE1)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE3)
- Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti Fungal Drug CI brief — competitive landscape report
- Anti Fungal Drug updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Anti Fungal Drug
What is Anti Fungal Drug?
How does Anti Fungal Drug work?
What is Anti Fungal Drug used for?
Who makes Anti Fungal Drug?
What development phase is Anti Fungal Drug in?
Related
- Manufacturer: University of California, San Francisco — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Fungal infections (specific indication not specified)
- Compare: Anti Fungal Drug vs similar drugs
- Pricing: Anti Fungal Drug cost, discount & access